Spontaneous bacterial peritonitis (SBP) in patients with cirrhotic liver disease is a serious complication that contributes to the high morbidity and mortality rate seen in this population. Currently, there is a lack of consensus amongst the research community on the clinical predictors of SBP as well as the risks and benefits of prophylactic antibiotic therapy in these patients. Pharmacological gastric acid suppression (namely with PPIs and H2RAs) are frequently prescribed for these patients, many times without a clear indication, and may contribute to gut bacterial overflow and SBP development. However, this remains controversial as there are conflicting findings in SBP prevalence between PPI/H2RA-users and non-users. In addition, studies show recent antibiotic use, whether for SBP prophylaxis or for another infectious process, appear to be associated with higher rates of SBP and drug-resistant organisms. Other researchers have also explored the link between zinc, platelet indices (MPV), and macrophage inflammatory protein-1 β (MIP-1β) levels in liver cirrhosis, all of which appear to be promising markers for classifying SBP risk and diagnosis. This literature review was limited by the number and quality of studies available as most are retrospective in nature. Thus, more ongoing, prospective studies and trials are needed to judge the true value of the findings in the studies reviewed in hopes that they can guide appropriate prevention, diagnosis, and management of SBP.
Introduction
Spontaneous bacterial peritonitis (SBP), an infection of the ascites fluid in the peritoneum that occurs in the absence of another infectious source, is a complication seen in patients with liver cirrhosis [1] . It carries potentially significant morbidity and mortality in this population due to their altered immunocompetency and overall disease burden [2] . SBP is generally theorized to be the result of gut bacteria translocation into the surrounding ascitic peritoneal fluid secondary to dysregulated local mucosal defense mechanisms and gastrointestinal hypomotility and is a sign of decompensated liver cirrhosis [3] . Clinical manifestations, though not always present, typically include fever, chills, and abdominal pain/discomfort, and may progress to mental status alterations and sepsis [4] . The prevalence of SBP in patients with liver cirrhosis ranges anywhere from twenty to fifty percent, depending on the study reviewed, with inpatient mortality rates as high as 32% [5] . True incidence and prevalence appear to be difficult to recognize as diagnostic ascitic fluid cultures can remain negative even in the presence of SBP [6] . In addition, some patients simply are asymptomatic through the course of the infection and would have otherwise remained missed cases if it were not for having a diagnostic or therapeutic paracentesis performed. And while those who stay asymptomatic are not burdened by the clinical manifestations that threaten their physiological state at the moment, studies suggest prior episodes of SBP may predispose them to more difficult to manage subsequent episodes [2] [5] [6] .
The diagnosis of SBP requires a paracentesis to obtain an ascites fluid sample and is based on a positive ascites fluid culture and polymorphonuclear (PMN) leukocyte count greater than 250/mm 3 [1] [7] . As with any invasive procedure, performing a paracentesis comes with certain risks, such as bleeding, infection, bowel perforation, and causing hemodynamically significant fluid shifts, and ultimately, the decision to proceed is that of clinical judgement and facility-based protocols, whether it is for diagnostic (i.e., suspicion of SBP in high risk individuals) or therapeutic (i.e., to ease work of breathing, relieve abdominal discomfort) purposes [8] . Some facilities may also routinely perform a diagnostic paracentesis for all admitted liver cirrhosis patients with ascites, regardless of SBP suspicion; however, this practice remains controversial due to the risks of the procedure [2] .
Current guidelines for inpatient SBP treatment include the use of an intravenous third-generation cephalosporin (such as ceftriaxone) or a quinolone [9] [10]. Additionally, clinicians may also choose to prescribe oral ciprofloxacin or trimethoprim-sulfamethoxazole for SBP prophylaxis in high-risk patients in both inpatient and outpatient settings [2] . Norfloxacin, a quinolone previously popular for SBP prophylaxis but has since been discontinued in the United [12] [13] . Those with a recent infection who are then discharged from the hospital have as high as a 41% risk of death or need for liver transplantation within six months [12] . There is also a subset of patients who become disqualified from liver transplantation while on the waitlist due to sepsis and multi-organ failure secondary to SBP. Better patient outcomes require both appropriate and timely antibiotic therapy prior to onset of hypotension and sepsis [14] . As for those who do proceed to liver transplantation, history of SBP occurrence pre-transplantation may be correlated with inferior graft function and even graft failure, with increased morbidity and mortality post-liver transplantation [15] .
Lastly, the medical costs related to SBP annually place tremendous strain on the healthcare system. Based on the U.S. Nationwide Inpatient Sample (NIS) data, costs associated with ICU admission and care with presumed infection in this patient population alone approximates $3 billion annually [6] .
Knowledge Gap
There is a current knowledge gap in managing liver cirrhosis patients at risk for 
Aim of Literature Review
The aim of this article is to explore the current state of knowledge regarding independent predictors of SBP development in liver cirrhosis patients as well as the potential utilization of trace elements (particularly zinc) and inflammatory biomarkers to stratify SBP risk and vulnerability. This is all in efforts to better assist clinical judgment in prioritizing antibiotic prophylactic treatment and reduce the risk of SBP development.
Methods
The online databases resourced for articles reviewed in the paper included who used PPIs developed serious infections, with the majority (75%) of infections being acid-suppression associated infections, including SBP, C. difficile, and pneumonia. Of those who developed infections while taking PPIs, the leading sources and types of infection involved were SBP (30%), pneumonia (25%), skin infections (23%), spontaneous bacteremia and septicemia (16%), C. difficile (5%), and UTI (1%). Of note, the researchers found no clinically significant difference in infection rates between patients who were on H2RA therapy and those who were not on any form of pharmacological gastric acid suppression [17] .
Another study by Goel [12] . The authors performed a six-month follow-up after discharge from the hospital and found PPI use to be an independent predictor of subsequent infections. Around 45% were readmitted for infections within this period, and a higher proportion of these patients were older in age, used PPIs, or received prophylactic therapy for SBP.
While the previous studies suggest a correlation between PPI use and SBP/infection rates, these findings do not go unopposed. 
Antibiotic Therapy in SBP
Another prominent area of study in examining independent predictors of SBP development is antibiotic therapy use in this group. According to Tandon et al., recent antibiotic use is associated with higher rates of SBP [13] . 
Zinc
Zinc, a physiological trace element with known functions in the immune system, has recently received some attention for its potential role in SBP development.
Zinc deficiency is a frequent finding in decompensated cirrhosis [20] . In a 2015 study performed by Mohammad et al., low zinc levels (defined as less than 60 µg/dL) were correlated with SBP development [21] . In this study, 35 of 54 (64.8%) SBP-positive subjects had a serum zinc level < 60 µg/dL, whereas only 45 of 122 (36.9%) SBP-negative subjects were found to have low serum zinc (p = 0.001). Sengupta et al. concluded in their 2015 study that serum zinc concentrations were inversely correlated with infection and ascites [20] . In addition, Sengupta et al. and Kar et al. examined and reported that zinc deficiency was linked to poorer clinical outcomes and shorter transplant-free survival [20] [22] . These latest findings indicate zinc may be an independent predictor of SBP in liver cirrhosis and have the potential to serve as a useful diagnostic and prognostic marker.
Platelet Indices and Inflammatory Biomarkers
Some researchers have turned to platelet activation and other inflammatory Open Journal of Gastroenterology 
Discussion
While ongoing further research is still necessary, the current state of knowledge regarding pharmacological gastric acid suppression therapy suggests there is stronger evidence relating PPI use with increased SBP incidence and overall poorer clinical outcomes in decompensated liver cirrhosis. Oftentimes, these agents are seen as fairly benign medications and can arguably be described as something clinicians prescribe out of habit or tradition rather than for a true indication [10] [25] . In fact, Ladato et al. argue there may be little efficacy of PPI use in the presence of hypertensive gastropathy, such as seen in liver cirrhosis patients [25] . By bringing more awareness to the potential adverse effects of pharmacologic gastric acid suppression particularly in this patient population, clinicians can better assess the risk-benefit ratio of its use prior to starting therapy, ensuring benefits outweigh the potential morbidity of SBP.
Based on the literature, recent antibiotic use is associated with higher rates of SBP infections and prevalence of DROs, presenting either through SBP or other infections. With the emergence of multi-drug resistant "superbugs", healthcare providers must be more conscientious about the risks related to inappropriate antibiotic prescription, particularly in caring for vulnerable groups such as in decompensated liver cirrhosis. Providers must also avoid indiscriminate antibiotic use and escalation in otherwise low-risk patients. The rise in antibiotic resistance has led to increased treatment failure with traditional methods and will continue to exhaust the availability of effective antibiotics, such as third-generation cephalosporins and ciprofloxacin in SBP treatment and prophylaxis respectively.
It will then only be a matter of time before they and other agents are rendered useless, leaving these patients completely defenseless against infections.
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In order to improve clinical management and establish updated guidelines for SBP diagnosis and treatment, further exploration of the role of zinc would increase the knowledge base of SBP pathophysiology. Zinc has known functions in immunocompetency and serves as an enzyme cofactor in a number of metabolic and cellular processes, plays a role in oxidative stress, and may also have antiinflammatory effects [21] [26] . With the rise of antibiotic resistance, it is becoming more difficult for clinicians to determine the risk-benefit ratio in prophylactically treating SBP. If further studies determine and support that zinc is indeed a significant independent predictor of SBP, perhaps zinc replacement can alter infection risk and/or overall outcomes. In essence, can zinc replacement delay or prevent decompensation, and if so, to what extent? With a greater understanding of such questions, providers can take a more proactive rather than reactive approach in hopes of significantly reducing morbidity and mortality in those with chronic liver disease and failure.
On a similar note, inflammatory biomarkers like MPV and MIP-1β appear to be promising indicators that can be utilized for SBP diagnosis. Use of inflammatory biomarkers to determine the need to initiate empiric antibiotic therapy in the absence of elevated PMN and/or while pending fluid culture reports is a topic worth exploring more. And if future research supports the utility of these biomarkers to assess for presence of ascitic fluid infections, a practice guideline change reflective of such may allow for earlier and proper diagnosis and treatment of SBP, with hopes of improving patient outcomes, reduce patient risk of need for more invasive diagnostic measures (i.e., paracentesis), and lower overall healthcare spending.
Conclusion
While this paper is limited by the relatively small number of studies available on this topic as well as the quality and type of studies (most are retrospective in nature), it sheds light on how much is still unknown regarding this disease process and how there is a need to change certain aspects of SBP clinical management in liver cirrhosis based on the high rates of morbidity and complications. In performing a literature search, it is clear more prospective, randomized controlled trials are required to better assess the risk versus protective factors for SBP development in liver cirrhosis. This is vital in judging the true value of the findings presented in the studies reviewed in this paper and will be a major milestone for the research community before updated evidence-based practice guidelines can be put forth.
